ethyl 2-propylimidazo[1,2-a]pyridine-3-carboxylate | 1338469-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: ethyl 2-propylimidazo[1,2-a]pyridine-3-carboxylate
• 英文别名: Ethyl 2-propylimidazo[1,2-a]pyridine-3-carboxylate
• CAS: 1338469-67-2
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: JYGXCDYUOZPERQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-propylimidazo[1,2-a]pyridine-3-carboxylate 在 水 、 lithium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-Propylimidazo[1,2-a]pyridine-3-carboxylic acid
  参考文献：
  名称：

  Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

  摘要：

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

  DOI：

  10.1021/jm5003606
• 作为产物：
  描述：

  丁酰乙酸乙酯 在 溴 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 0.33h， 生成 ethyl 2-propylimidazo[1,2-a]pyridine-3-carboxylate
  参考文献：
  名称：

  Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

  摘要：

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

  DOI：

  10.1021/jm5003606

文献信息

• CBr₄ Mediated Oxidative C–N Bond Formation: Applied in the Synthesis of Imidazo[1,2-α]pyridines and Imidazo[1,2-α]pyrimidines
  作者：Congde Huo、Jing Tang、Haisheng Xie、Yajun Wang、Jie Dong

  DOI：10.1021/acs.orglett.6b00137

  日期：2016.3.4

  tetrabromide mediated oxidative carbon–nitrogen bond formation of 2-aminopyridines or 2-aminopyrimidines with β-keto esters or 1,3-diones, leading to a variety of complex imidazo[1,2-α]pyridines or imidazo[1,2-α]pyrimidines, is reported. The reactions were realized under mild and metal-free conditions.

  四溴化碳介导的2-氨基吡啶或2-氨基嘧啶与β-酮酸酯或1,3-二酮的氧化碳-氮键形成，导致形成各种复杂的咪唑并[1,2-α]吡啶或咪唑并[1，报道了2-α]嘧啶。反应在温和且无金属的条件下进行。
• 2-Aminopyridines as an α-Bromination Shuttle in a Transition Metal-Free One-Pot Synthesis of Imidazo[1,2-<i>a</i> ]pyridines
  作者：Irwan Iskandar Roslan、Kian-Hong Ng、Gaik-Khuan Chuah、Stephan Jaenicke

  DOI：10.1002/adsc.201501012

  日期：2016.2.4

  A wide range of imidazo[1,2‐a]pyridines are accessible from cheap and readily available 2‐aminopyridines and 1,3‐dicarbonyl compounds using a unique CBrCl3/2‐aminopyridine system for bromination at the α‐carbon. 2‐Aminopyridine is not only the substrate but also acts as a bromination shuttle, transferring the bromine atom from CBrCl3 to the α‐carbon of the 1,3‐dicarbonyl. The reaction mechanism involves

  使用独特的CBrCl 3 / 2-氨基吡啶体系在α-碳上进行溴化，可以从便宜且容易获得的2-氨基吡啶和1,3-二羰基化合物中获得各种咪唑并[1,2- a ]吡啶。2-氨基吡啶不仅是底物，而且还用作溴化穿梭，将溴原子从CBrCl 3转移到1,3-二羰基的α-碳上。该反应机理涉及一系列可逆步骤，包括具有环状过渡态的加成反应，以形成溴血红素中间体。在这种无过渡金属的单锅合成中，在温和的条件下和较短的反应时间下，分离出的产率高达97％。
• Synthesis of Imidazo[1,2-a]pyridines by the Bis(acetyloxy)(phenyl)-λ³-iodane-Mediated Oxidative Coupling of 2-Aminopyridines with β-Keto Esters and 1,3-Diones
  作者：Wei Yu、Xianpei Wang、Lijuan Ma

  DOI：10.1055/s-0030-1260106

  日期：2011.8

  2-aminopyridines and β-keto esters by using bis(acetyloxy)(phenyl)-λ³-iodane as an oxidant and boron trifluoride etherate as a catalyst. The amount of catalyst plays a key role in determining the course of the reaction. Whereas the use of 0.2 equivalents of catalyst ensures the generation of imidazo[1,2-a]pyridines, raising the amount of catalyst to 1.0 equivalents results in exclusive α-acetoxylation of

  咪唑并[1,2一]吡啶-3-羧酸盐，可直接由2-氨基吡啶和β酮酯通过使用双（乙酰基氧基）制备（苯基）-λ ³ -iodane作为氧化剂和三氟化硼醚作为催化剂。催化剂的量在确定反应过程中起关键作用。尽管使用0.2当量的催化剂可确保生成咪唑并[1,2- a ]吡啶，但将催化剂的量提高至1.0当量可导致β-酮酯的独家α-乙酰氧基化。2-氨基吡啶也可以与1，3-二酮反应，得到3-酰基咪唑并[1,2- a ]吡啶。 杂环-多环-环化-氧化-偶联
• TBAI-catalyzed oxidative coupling of aminopyridines with β-keto esters and 1,3-diones—synthesis of imidazo[1,2-a]pyridines
  作者：Lijuan Ma、Xianpei Wang、Wei Yu、Bing Han

  DOI：10.1039/c1cc13568f

  日期：——

  TBAI could catalyze the direct oxidative C–N coupling of 2-aminopyridines with β-keto esters and 1,3-diones, which affords imidazo[1,2-a]pyridines as the products. The reaction was realized under metal-free conditions by using tert-butyl hydroperoxide (TBHP) as the oxidant.

  TBAI可以催化2-氨基吡啶与β-酮酯和1,3-二酮的直接氧化C–N偶联反应，生成咪唑[1,2-a]吡啶作为产物。该反应在无金属条件下实现，采用叔丁基过氧化氢（TBHP）作为氧化剂。
• Lead Optimization of a Novel Series of Imidazo[1,2-<i>a</i>]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent
  作者：Sunhee Kang、Ryang Yeo Kim、Min Jung Seo、Saeyeon Lee、Young Mi Kim、Mooyoung Seo、Jeong Jea Seo、Yoonae Ko、Inhee Choi、Jichan Jang、Jiyoun Nam、Seijin Park、Hwankyu Kang、Hyung Jun Kim、Jungjun Kim、Sujin Ahn、Kevin Pethe、Kiyean Nam、Zaesung No、Jaeseung Kim

  DOI：10.1021/jm5003606

  日期：2014.6.26

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.